📊 ASND Key Takeaways
Is Ascendis Pharma A/S (ASND) a Good Investment?
Unable to conduct meaningful fundamental analysis due to unavailability of financial data. Critical metrics including revenue, profitability, balance sheet items, and cash flow are all absent from available SEC filings. Analysis cannot proceed without access to basic financial statements.
Ascendis Pharma’s fundamentals improved materially in 2025, with total revenue rising to about €720 million from €364 million in 2024 and product revenue becoming the dominant driver, which points to better growth quality than prior periods that relied more on licensing revenue. Gross profitability is strong for a commercial-stage biotech, and operating losses narrowed sharply, but the company still carries negative equity and meaningful financial liabilities, so the story is a high-growth but not yet fully de-risked transition to sustained profitability.
Why Buy Ascendis Pharma A/S Stock? ASND Key Strengths
- Insufficient data for assessment
- Revenue growth accelerated sharply in 2025, with commercial product revenue reaching roughly €684 million and reducing reliance on one-time collaboration payments
- Gross margin remains very high, supporting substantial earnings leverage if operating expenses normalize relative to sales
- Liquidity is still solid with about €616 million in cash at December 31, 2025, giving the company runway while commercialization scales
ASND Stock Risks: Ascendis Pharma A/S Investment Risks
- No revenue data available - cannot assess commercial viability
- Missing profitability metrics - unable to determine financial health
- Lack of balance sheet data - cannot evaluate liquidity or solvency position
- No cash flow information - cannot assess sustainability or burn rate
- Data freshness unknown - filings may be outdated or incomplete
- The company remains unprofitable on a full-year basis, with a 2025 net loss of about €228 million despite major revenue growth
- Balance sheet quality is pressured by negative equity and large borrowings plus derivative liabilities tied to financing structures
- Operating expense growth remains heavy, especially SG&A tied to global launches, so margin improvement could stall if revenue execution slows
Key Metrics to Watch
- Revenue generation and YoY growth
- Gross profit and operating margins
- Cash position and runway
- R&D spending and pipeline progress
- Balance sheet strength and debt levels
- Commercial product revenue growth versus SG&A growth, especially for SKYTROFA and YORVIPATH
- Cash flow from operations and progress from operating loss toward sustained operating profit
Ascendis Pharma A/S (ASND) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ASND Profit Margin, ROE & Profitability Analysis
ASND vs Healthcare Sector: How Ascendis Pharma A/S Compares
How Ascendis Pharma A/S compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ascendis Pharma A/S Stock Overvalued? ASND Valuation Analysis 2026
Based on fundamental analysis, Ascendis Pharma A/S has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ascendis Pharma A/S Balance Sheet: ASND Debt, Cash & Liquidity
ASND Revenue Growth, EPS Growth & YoY Performance
ASND SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ascendis Pharma A/S (CIK: 0001612042)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASND
What is the AI rating for ASND?
Ascendis Pharma A/S (ASND) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASND's key strengths?
Claude: Insufficient data for assessment. ChatGPT: Revenue growth accelerated sharply in 2025, with commercial product revenue reaching roughly €684 million and reducing reliance on one-time collaboration payments. Gross margin remains very high, supporting substantial earnings leverage if operating expenses normalize relative to sales.
What are the risks of investing in ASND?
Claude: No revenue data available - cannot assess commercial viability. Missing profitability metrics - unable to determine financial health. ChatGPT: The company remains unprofitable on a full-year basis, with a 2025 net loss of about €228 million despite major revenue growth. Balance sheet quality is pressured by negative equity and large borrowings plus derivative liabilities tied to financing structures.
What is ASND's revenue and growth?
Ascendis Pharma A/S reported revenue of N/A.
Does ASND pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
Where can I find ASND SEC filings?
Official SEC filings for Ascendis Pharma A/S (CIK: 0001612042) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASND's EPS?
Ascendis Pharma A/S has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ASND a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ascendis Pharma A/S has a BUY rating with 44% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ASND stock overvalued or undervalued?
Valuation metrics for ASND: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ASND stock in 2026?
Our dual AI analysis gives Ascendis Pharma A/S a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASND's free cash flow?
Ascendis Pharma A/S's operating cash flow is N/A, with capital expenditures of N/A.
How does ASND compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).